- Accesswire•yesterdayBlog Coverage Dynavax Releases New Data Showing That its Vaccine HEPLISAV-B Offers Higher Seroprotection Against Hepatitis B
LONDON, UK / ACCESSWIRE / October 27, 2016 / Active Wall St. blog coverage looks at the headline from Dynavax Technologies Corp. (NASDAQ: DVAX ). The company announced on October 26, 2016, the results ...
Dynavax Technologies Corporation today announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, pursuant to which Dynavax has agreed to ...
- Marketwired•2 days agoDynavax Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection in Populations Known to Have a Reduced Immune Response to Currently Licensed Vaccines
Dynavax Technologies Corporation today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ . The ...
Dynavax Technologies Corporation (DVAX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||9.65 x 200|
|Ask||10.00 x 200|
|Day's Range||9.35 - 9.95|
|52wk Range||9.35 - 29.86|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.19|
|Avg Vol (3m)||1,513,580|
|Dividend & Yield||N/A (N/A)|